EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Tumour necrosis factor a production by polymorphonuclear neutrophils treated with mouse anti-human CD19 monoclonal antibody



Tumour necrosis factor a production by polymorphonuclear neutrophils treated with mouse anti-human CD19 monoclonal antibody



Cell Biochemistry & Function 22(4): 207-211, July



Polymorphonuclear neutrophils (PMNs) play pivotal roles as phagocytic cells in immune defence against bacteria and parasites, exerting their effects by production of reactive oxygen species, several cytokines, chemokines and by phagocytotic reaction. In our investigation of properties of activated PMNs, we discovered that one of the two kinds of mouse anti-human CD19 monoclonal antibodies (mAbs) clone SJ25-C1, weakly binds to freshly prepared PMNs. Moreover, the treatment of freshly prepared PMNs with anti-CD19 mAb (clone SJ25-C1) at 37degreeC for 6 h induces the production and the secretion of turnout necrosis factor alpha (TNF alpha) by PMNs in vitro which was detectable in culture supernatants by bioassay using mouse cell line L929 cells. The concentration of TNF alpha secreted into the culture supernatant of PMNs cultured in the presence of anti-CD19 mAb (clone SJ25-C1) was higher than those of PMNs treated at 37degreeC for 6 h with various PMN activators, such as anti-CD24 mAb, granulocytes-macrophage colony stimulation factor (GM-CSF) or interferon gamma (IFN gamma). In contrast, another clone of anti-CD 19 mAb, HD37, did not bind to freshly prepared PMNs and failed to produce TNF alpha. To confirm that anti-CD19 mAb (clone SJ25-C1)-treated PMNs definitely produce TNF alpha, we measured the levels of intracellular expression of TNF a in PMNs permeabilized by saponin. These cells were treated with fluorescence-conjugated mouse anti-human TNF alpha mAb for detection of intracellular TNF alpha expression. Consequently, large amounts of intracellular TNF alpha were detected in PMNs treated with anti-CD19 mAb (clone SJ25-C1) but not in those treated with anti-CD19 mAb (clone HD37). Copyright Copyright 2004 John Wiley & Sons, Ltd.

(PDF emailed within 1 workday: $29.90)

Accession: 012714327

Download citation: RISBibTeXText



Related references

Tumour necrosis factor alpha production by polymorphonuclear neutrophils treated with mouse anti-human CD19 monoclonal antibody. Cell Biochemistry and Function 22(4): 207-211, 2004

Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody. Annals of the Rheumatic Diseases 59(Supplement 1): i44-i45, 2000

Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release. European Cytokine Network 7(4): 751-755, 1996

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Annals of the Rheumatic Diseases 73(1): 161-169, 2014

Treatment of human b cell lymphoma with anti cd19 monoclonal antibody and with a combination of anti cd19 and il 2. Groopman, J E , D W Golde And C H Evans (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 100 Mechanisms Of Action And Therapeutic Applications Of Biologicals in Cancer And Immune Deficiency Disorders; Hoffman-La Roche-Smith Kline And French-Ucla Symposium, Keystone, Colorado, Usa, April 23-30, 1988 Xix+406p Alan R Liss, Inc : New York, New York, Usa Illus 293-304, 1989

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Annals of the Rheumatic Diseases 61 Suppl 2: Ii70-Ii73, 2002

Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. International Angiology 24(3): 304-307, 2005

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Annals of the Rheumatic Diseases 74(2): 430-436, 2015

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 60(7): 660-669, 2001

Increased surface expression of CD11b/c and CD18 appears to be dissociated from anti-CD11b/c monoclonal antibody stimulated O2- anion generation in in vivo Escherichia coli lipopolysaccharide and tumor necrosis factor-alpha-treated rat neutrophils. Shock 2(4): 289-295, 1994

Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Annals of the Rheumatic Diseases 61(6): 560-561, 2002